

1 **Supplementary Information**

2 **(S)-Oxiracetam is the Active Ingredient in Oxiracetam that Alleviates**
3 **the Cognitive Impairment Induced by Chronic Cerebral**
4 **Hypoperfusion in Rats**

5 Wan li ^{a,b}, Huihui Liu^c, Hanjie Jiang ^{a,b}, Chen Wang ^{a,b}, Yongfei Guo ^{a,b}, Yi Sun ^{a,b}, Xin
6 Zhao ^{a,b}, Xin Xiong^d, Xianhua Zhang^d, Ke Zhang ^{a,b}, Zongxiu Nie^{c*}, Xiaoping Pu ^{a,b*}

7 ^a National Key Research Laboratory of Natural and Biomimetic Drugs, Peking
8 University, Beijing 100191, PR China

9 ^b Department of Molecular and Cellular Pharmacology, School of Pharmaceutical
10 Sciences, Peking University, Beijing 100191, PR China

11 ^c Key Laboratory of Analytical Chemistry for Living Biosystems, Institute of Chemistry
12 Chinese Academy of Sciences, Beijing 100190, PR China

13 ^d Department of Pharmacy, Peking University Third Hospital, Beijing 100191, PR
14 China

15 * Corresponding authors:

16 Zongxiu Nie

17 Key Laboratory of Analytical Chemistry for Living Biosystems, Institute of Chemistry
18 Chinese Academy of Sciences, Zhongguancun North First Street 2, Beijing, PR China,
19 100190. Tel: +86-10-6261-8240; Fax: +86-10-6261-8240. E-mail: znjie@iccas.ac.cn

20 Xiaoping Pu

21 Department of Molecular and Cellular Pharmacology, School of Pharmaceutical
22 Sciences, Peking University, 38 Xueyuan Rd. Haidian District, Beijing, China, 100191.
23 Tel: +86-10-8280-2431; Fax: +86-10-8280-2431; E-mail: 11956170@pku.edu.cn

24

1 **Experimental conditions of Morris water maze**

2 The Morris water maze (SLY-ETS, Beijing Shuolinyuan Technology Co., Ltd.) was a
3 black and circular pool (180 cm in diameter, 60 cm in height, filled to a depth of 45 cm
4 with water at 23 °C) that was geographically divided into four equal quadrants
5 (Northeast, Southeast, Southwest, and Northwest) and each quadrant was marked by a
6 different visual cue. Four points that were designed as North, South, East and West
7 served as the starting points where the rats were gently lowered into the water, with its
8 head facing the wall of the water maze. A circular black escape platform 10 cm in
9 diameter (2 cm below the water surface) was placed in the center of the southwest
10 quadrant and located at this location for escape throughout the testing period.

11 **Preparation of matrix**

12 To obtain 1, 5-DAN hydrochloride, 39.5 mg 1, 5-DAN was dissolved in 500 μL 1 mol/L
13 hydrochloride and 4 mL distilled water by sonification. And then, 4.5 mL ethanol was
14 added to the matrix solution.

15 **Preparation of mixture standard solution**

16 A mixture standard solution containing taurine, L-aspartate, L-glutamate, glutamine,
17 N-acetylaspartate, ascorbic acid, citric acid, glutathione, AMP, ADP, ATP, GMP,
18 glucose at 50 μM each was prepared in water.

19 **Tissue Homogenate Preparation.**

20 Brain tissue samples were weighed and homogenized (1 g: 5 m L) in 80% MeOH on
21 ice using a ultrasonic processor. After centrifugation at 10,000 × g for 15 min at -4 °C,
22 the supernatant was collected, and the precipitant was then extracted (1 g: 5 mL) with

1 CHCl₃/MeOH (1:1, v/v) on ice by sonification for three time with an interval of 10min.
2 Each sample was then, centrifuged at 10,000 × g for 15 min at -4°C, the supernatant
3 was collected. Furthermore, two parts of supernatant were mixed and dried under
4 nitrogen. The resultant samples were stored at -80°C. Samples were dissolved (1 g: 5 m
5 L) in 80% MeOH and centrifuged at 18,000 × g for 10 min at -4 °C prior to analysis.
6 50 μM 4-hydroxybenzophenone were used as the internal standard in this experiment.
7
8

1 **Supplementary Table. 1**

2 Multiple reaction monitoring (MRM) transition and optimal DP and CE for each metabolite.

Analyte	Parent ion	Product ion	DP(V)	CE (V)
Taurine	124.1	79.8	60	30
Aspartate	131.9	87.9	50	20
Glutamine	144.9	128.1	55	15
Glutamate	145.9	102.1	40	20
N-acetylaspartate	173.9	130.1	45	18
Ascorbic acid	174.9	114.9	45	18
Glucose	179.1	89.05	80	15
Citric acid	191	110.9	50	15
Glutathione	306	143.1	80	23
GMP	362.0	211.0	70	27
AMP	346.1	133.9	100	50
ADP	426.2	134.1	90	35
ATP	506.1	158.9	100	40
4-Hydroxybenzophenone	124.1	79.8	70	40

3 DP (V): declustering potential, CE (V): collision energy, AMP: adenosine monophosphate, ADP:

4 adenosine diphosphate, ATP: adenosine triphosphate, GMP: guanosine monophosphate.

5


1 **Supplementary Table. 2**

2 Peak area recorded for altered metabolites extracted from cortex of the 2-VO rats.

Name	Peak area			
	Sham	Model	Rso	So
1. Glucose (E+06)	7.92 ± 3.27	7.2 ± 2.19	10.24 ± 4.60	8.87 ± 3.57
2. Citric acid (E+06)	6.47 ± 1.40	14.94 ± 8.20*	8.83 ± 2.55	7.95 ± 2.54
3. ATP (E+03)	1.65 ± 0.44	0.81 ± 0.30**	0.76 ± 0.32	0.79 ± 0.33
4. ADP (E+05)	5.04 ± 0.68	0.83 ± 0.82***	2.94 ± 0.77**	2.57 ± 0.89**
5. AMP (E+05)	1.93 ± 0.53	0.15 ± 0.14***	0.43 ± 0.28*	0.66 ± 0.36**
6. GMP (E+05)	12.89 ± 1.65	2.43 ± 2.96***	5.96 ± 2.39*	7.12 ± 2.29*
7. Glutamate (E+07)	11.03 ± 0.95	5.47 ± 2.39***	8.14 ± 1.29*	8.43 ± 1.34*
8. Glutamine (E+06)	9.39 ± 1.99	3.38 ± 2.29***	7.23 ± 1.50**	6.87 ± 1.93*
9. Aspartate (E+07)	4.12 ± 0.54	1.35 ± 1.17***	2.31 ± 0.92	2.16 ± 0.62
10. N-acetylaspartate (E+06)	6.75 ± 0.35	1.15 ± 1.34***	3.44 ± 0.96**	3.30 ± 1.11*
11. Glutathione (E+06)	7.53 ± 2.07	0.80 ± 1.19***	3.88 ± 1.84**	3.86 ± 2.02**
12. Ascorbic acid (E+07)	9.19 ± 0.63	3.31 ± 2.20***	8.10 ± 1.08***	7.47 ± 1.77**
13. Taurine (E+07)	6.74 ± 0.56	3.64 ± 2.00**	6.52 ± 0.63*	5.81 ± 1.34
14. 4-Hydroxybenzophenone (E+04)	3.17 ± 0.18	3.37 ± 0.06*	3.01 ± 0.23**	3.08 ± 0.24*


3 So: (S)-oxiracetam; Rso: oxiracetam. Data were presented as mean ± SD, n = 5 - 6 per group. One-
 4 way ANOVA was used to analyze the differences of groups. ##*P* < 0.01, ###*P* < 0.001 vs. sham group;
 5 **P* < 0.05, ***P* < 0.01 vs. model group.

6
 7
 8
 9
 10
 11
 12



Supplementary Figure 1 | Structural formula of oxiracetam (a), (*S*)-oxiracetam (b) and (*R*)-oxiracetam (c).

1
2
3
4
5
6
7
8
9
10




Supplementary Figure 2 | Diagrammatic representation of two experimental protocols. (a)

Evaluation of the nootropic effects of *S*-oxiracetam in the chronic phase of 2-VO model. (b) Mass


spectrometry imaging of small molecules in the acute phase of 2-VO model. So: (*S*)-oxiracetam; Ro:

(*R*)-oxiracetam; Rso: oxiracetam.

11
12
13
14
15
16



1
2 **Supplementary Figure 3 | The swimming speed in the navigation test of Morris water maze**
3 **test.** So: (*S*)-oxiracetam; Ro: (*R*)-oxiracetam; Rso: oxiracetam. Data were presented as mean \pm SEM,
4 n = 7-9 per group. The swimming speed in the navigation training was analyzed using Two-way
5 ANOVA of repeated measures.
6



1

2 **Supplementary Figure 4 | (S)- oxiracetam increased SOD activity (a) and decreased MDA**

3 **content (b) in rats' cortex induced by 2-VO.** So: (S)-oxiracetam; Ro: (R)-oxiracetam; Rso:

4 oxiracetam. Data were presented as means \pm SEM, n = 6-7 per group. One-way ANOVA was used

5 to analyze the differences of groups. [#] $p < 0.05$, ^{##} $p < 0.01$ vs. Sham group, ^{*} $p < 0.05$ vs. Model

6 group.

7